Previous Close | 3.6000 |
Open | 3.6000 |
Bid | 3.5000 |
Ask | 3.7500 |
Strike | 85.00 |
Expire Date | 2026-01-16 |
Day's Range | 3.6000 - 3.6000 |
Contract Range | N/A |
Volume | |
Open Interest | 112 |
PBH vs. ABT: Which Stock Is the Better Value Option?
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
NORTHAMPTON, MA / ACCESSWIRE / April 23, 2024 / Abbott Eleven new HeartMates with 11 inspiring stories recognized at Abbott HeartMates Draft Day event in NYC. Abbott Just a week before the pro football draft, Abbott held a high-profile draft day experience ...